News:
Brokerage
Posted: November 23, 2021
RegenLab USA holds ribbon cutting at Brooklyn site
Brooklyn, NY RegenLab USA held a ribbon cutting ceremony to mark the opening of its new research and manufacturing facility at BioBAT at the Brooklyn Army Terminal.
Joining to welcome RegenLab USA to the borough were a host of prominent civic and business leaders including Susan Rosenthal, senior vice president of life sciences & healthcare at New York City Economic Development Corp. (NYCEDC); Dr. Eva Cramer, president at BioBAT and vice president for biotechnology & scientific affairs at SUNY Downstate Medical Center; and Randy Peers, president and CEO of the Brooklyn Chamber of Commerce.
The Switzerland-based company specializes in cellular therapy and tissue engineering medical devices including platelet-rich plasmas and bone marrow cells, and its major foreign investment in the area will create up to 150 jobs. Between operations, research, design and manufacturing positions, jobs at the site on average pay $110,000 per year and will contribute to the area’s arrival as a biotech hub. RegenLab USA’s new facility occupies 15,000 s/f.
“Our search for a manufacturing base in the United States was relatively quick as Brooklyn immediately stood out as an ideal home,” said Antoine Turzi, EO of RegenLab USA.
“We are excited to create jobs and establish ourselves in the American market right here in Brooklyn, a booming hub of bio and life sciences companies anchored by a skilled workforce and vibrant culture. We are grateful to Dr. Cramer, New York City Economic Development Corp (NYCEDC) President Rachel Loeb, and Randy Peers at the Brooklyn Chamber of Commerce for welcoming us to Brooklyn and putting into place tools that will facilitate success for RegenLab USA.”
The Brooklyn Chamber of Commerce and RegenLab USA will be hosting a life sciences symposium in May 2022 to discuss clinical advances in cell therapies and highlight the unique features of BioBAT that make it an attractive option for companies looking to grow in the field.
Tags:
Brokerage
MORE FROM Brokerage
Adler of Rand Commercial brokers $2.3 million sale of retail assemblage in Yonkers
Yonkers, NY Rand Commercial negotiated the June 12, 2026 sale of an 11,000 s/f retail assemblage at 245, 247, 251, and 253 South Bdwy. for $2.3 million to an owner-user.
Quick Hits
Columns and Thought Leadership
A fresh start - by Shallini Mehra and Amit Doshi
For the past several years, the New York City multifamily housing market has been defined by disruption. The combined impact of the HSTPA rent laws and a sharply higher interest rate environment has fundamentally reduced
Tri-state capital migrates nationally amid regulation pressure - by Reese Weaver
New York tri-state multifamily investors are increasingly reallocating capital to less-regulated markets across the U.S. as rent control and legislative risk erode returns at home. With over 60% of New York City’s rental housing stock classified as rent-stabilized, the traditional value-add model — buying under-performing buildings,
The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman
July 1, 2025 is the deadline for US banks to begin to adopt Basel III banking standards and July 14, 2025 is the deadline for U.S. banks to adopt ISO 20022 messaging standards. Both will have a significant effect on the banking and commercial real estate (CRE) finance sectors.
The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian
There was a time when an offering memorandum (OM) was pretty bare bones, some photos, a few bullet points on income, and a rent roll thrown in at the back. That used to get the job done. Not anymore. In 2025, buyers are sharper, faster, and more selective. They’re looking
